Hite Christopher
EVP & Chairman, Partnering
Hite Christopher has filed 8 SEC Form 4 filings (14 transaction rows) across 1 company, with disclosures dating back to 2025. 8 of those filings fall inside the rolling window. Most recent filing: Sep 24, 2026.
On the most recent filing, Hite Christopher is listed as EVP & Chairman, Partnering at Royalty Pharma plc. Inside the rolling window, Hite Christopher reported no open-market purchases and 4 open-market sales totaling $27.4M in RPRX. The largest disclosed transaction in the window is a sale of 150,000 RPRX shares on Jun 23, 2026, worth $8.2M.
Companies traded
Other insiders at RPRX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$27.4M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Hite Christopher made?
Hite Christopher has filed 8 SEC Form 4 filings (14 transaction rows) across 1 company since 2025.
Which companies does Hite Christopher trade?
Hite Christopher has filed SEC Form 4 disclosures for 1 company, including RPRX.
When was Hite Christopher's most recent SEC Form 4 filing?
Hite Christopher's most recent SEC Form 4 filing on Tracefour is dated Sep 24, 2026.
What is Hite Christopher's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Hite Christopher is listed as EVP & Chairman, Partnering.
What is Hite Christopher's total buy and sell value in the current window?
Inside the rolling retention window, Hite Christopher bought $0 and sold $27.4M based on SEC Form 4 filings.
What was Hite Christopher's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 150,000 RPRX shares on 2026-06-23, worth $8.2M, per SEC Form 4 filings.